Shots:

• The extended agreement allows Cantargia to create and use additional CHO cell lines engineered utilizing BioWa’s POTELLIGENT technology and to develop and commercialize CAN04 developed via CHO cell lines
• In 2015- Cantargia signed an agreement with BioWa’s technology in advancing its CAN04 to P-IIa clinical study for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC)
• CAN04 (nidanilimab) targeting IL1RAP- currently being evaluated in P-I/IIa CANFOUR study as a monothx. & combination therapy focusing on NSCLC & PDAC. POTELLIGENT technology reduces fucose in the carbohydrate structure of an Ab using fucosyl transferase-knockout CHO cell line thus enhances ADCC activity of an Ab in vitro & increases efficacy in vivo

Click here to­ read full press release/ article | Ref: Business wire | Image: Cision News